The FDA has requested clinical trial data from the manufacturer of saxagliptin, Bristol-Myers Squibb and AstraZeneca, to…
Onglyza
BMS Presents Study Results for Type 2 Diabetes Drug Onglyza (saxagliptin)
AstraZeneca and Bristol-Myers Squibb have announced the full results of the SAVOR clinical trial of Onglyza (saxagliptin…
FDA To Re-Evaluate Type 2 Diabetes Drugs Following New Research
The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of panc…
Type 2 Diabetes Drug ONGLYZA Approved for Sale in Europe
The European Commission has approved Bristol-Myers Squibb Company and AstraZeneca's ONGLYZA (saxagliptin) for use as a c…
Adding ONGLYZA to Insulin in Adults with Type 2 Diabetes Found Effective
Results of an investigational Phase 3b clinical study, presented by Bristol-Myers Squibb Company and AstraZeneca at the …
Type 2 Diabetes Drug, ONGLYZA, Approved for Treatment of Renal Impairment by EU
The European Commission approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabet…
New Type 2 Diabetes Drug Kombiglyze XR Now Available Across the US
Bristol-Myers Squibb Company and AstraZeneca announced that type 2 diabetes drug Kombiglyze XR (saxagliptin and metformi…
KOMBIGLYZE XR Approved for the Treatment of Type 2 Diabetes
Bristol-Myers Squibb Company and AstraZeneca announced FDA approval of KOMBIGLYZE™ XR, the first and only once-a-day met…
